• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度他雄胺、坦索罗辛和联合治疗对良性前列腺增生和前列腺增大患者储尿和排尿的影响:阿夫唑嗪和坦索罗辛联合治疗研究的 2 年结果。

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

机构信息

Division of Urology, University of Buenos Aires, Buenos Aires, Argentina.

出版信息

Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.

DOI:10.1038/pcan.2009.37
PMID:19901936
Abstract

This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride (0.5 mg), tamsulosin (0.4 mg), and their combination on storage and voiding symptoms in 4844 men aged > or =50 years with moderate-to-severe lower urinary tract symptoms (International Prostate Symptom Score > or =12), prostate volume (PV) > or =30 cm(3) and PSA 1.5-10 ng ml(-1). After 24 months, combination treatment achieved significantly greater mean reductions in both voiding and storage symptoms than either monotherapy, in each of the three baseline PV tertiles (30 to <42, 42 to <58, > or =58 cm(3)). Dutasteride was as effective as tamsulosin for control of storage symptoms, but provided significantly greater relief of voiding symptoms than tamsulosin.

摘要

本文报道了多中心、随机、双盲的阿夫唑嗪和坦索罗辛联合治疗(CombAT)研究的事后分析结果,该研究旨在探讨度他雄胺(0.5mg)、坦索罗辛(0.4mg)及其联合应用对 4844 名年龄≥50 岁、中重度下尿路症状(国际前列腺症状评分≥12)、前列腺体积(PV)>30cm³和 PSA 1.5-10ng/ml 的男性的储尿和排尿症状的影响。24 个月后,联合治疗在每个基线 PV 三分位(30-<42、42-<58、≥58cm³)中均显著优于单药治疗,使排尿和储尿症状的平均改善程度更大。度他雄胺在控制储尿症状方面与坦索罗辛一样有效,但在缓解排尿症状方面明显优于坦索罗辛。

相似文献

1
The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.度他雄胺、坦索罗辛和联合治疗对良性前列腺增生和前列腺增大患者储尿和排尿的影响:阿夫唑嗪和坦索罗辛联合治疗研究的 2 年结果。
Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.
2
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.度他雄胺、坦索罗辛及联合治疗对良性前列腺增生和前列腺肿大男性下尿路症状的影响:CombAT研究的2年结果
J Urol. 2008 Feb;179(2):616-21; discussion 621. doi: 10.1016/j.juro.2007.09.084. Epub 2007 Dec 21.
3
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.基线参数对有症状的良性前列腺增生和前列腺肿大男性使用度他雄胺、坦索罗辛及联合治疗后国际前列腺症状评分变化的影响:CombAT研究的2年数据
Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.
4
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.度他雄胺联合坦索罗辛或单药治疗良性前列腺增生伴下尿路症状患者后国际前列腺症状评分变化的基线变量影响:CombAT 研究 4 年结果。
BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9.
5
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.联合治疗比单独治疗对前列腺增生(BPH)患者的临床效果:基线特征的 4 年随机、双盲阿夫唑嗪和坦索罗辛联合治疗(CombAT)试验结果。
BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.
6
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.度他雄胺与坦索罗辛联合治疗中重度良性前列腺增生和前列腺肿大的男性:CombAT(阿夫唑嗪与坦索罗辛联合)试验原理及研究设计
Contemp Clin Trials. 2007 Nov;28(6):770-9. doi: 10.1016/j.cct.2007.07.008. Epub 2007 Aug 2.
7
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.度他雄胺、坦索罗辛及其联合用药对中重度良性前列腺增生男性患者报告的生活质量和治疗满意度的影响:CombAT试验的2年数据
BJU Int. 2009 Apr;103(7):919-26. doi: 10.1111/j.1464-410X.2009.08196.x. Epub 2009 Feb 23.
8
The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.度他雄胺或坦索罗辛单药及联合治疗对伴有下尿路症状(LUTS)和良性前列腺增生(BPH)的男性患者的储尿和排尿症状的影响:来自阿夫唑嗪和坦索罗辛联合治疗(CombAT)研究的 4 年数据。
BJU Int. 2011 May;107(9):1426-31. doi: 10.1111/j.1464-410X.2011.10129.x. Epub 2011 Feb 23.
9
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.度他雄胺、坦索罗辛和联合治疗对中重度良性前列腺增生患者报告的生活质量和治疗满意度的影响:来自 CombAT 研究的 4 年数据。
Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7.
10
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.在患有下尿路症状和膀胱过度活动症的男性中,使用或不使用坦索罗辛的缓释托特罗定:对通过国际前列腺症状评分评估的泌尿症状的影响。
BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x. Epub 2008 May 26.

引用本文的文献

1
Association between oral frailty and lower urinary tract symptoms among middle-aged and older adults in community-dwelling individuals: a cross-sectional study.社区居住的中老年人口腔脆弱与下尿路症状之间的关联:一项横断面研究。
Int Urol Nephrol. 2024 Jun;56(6):1803-1810. doi: 10.1007/s11255-023-03878-6. Epub 2024 Jan 12.
2
Correlation between Higher Aging Males' Symptoms Scores and a Higher Risk of Lower Urinary Tract Symptoms.老年男性症状评分较高与下尿路症状风险较高之间的相关性。
J Clin Med. 2023 Dec 6;12(24):7528. doi: 10.3390/jcm12247528.
3
Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
从用于良性前列腺增生的α受体阻滞剂和5α还原酶抑制剂长期联合治疗方案中停用一种药物的临床结局
Int Urol Nephrol. 2023 Apr;55(4):845-851. doi: 10.1007/s11255-023-03476-6. Epub 2023 Feb 10.
4
Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan.碘-125低剂量率近距离放射治疗局限性前列腺癌的临床疗效:日本单机构回顾
J Contemp Brachytherapy. 2022 Apr;14(2):157-168. doi: 10.5114/jcb.2022.115380. Epub 2022 Apr 7.
5
The impact of preoperative lower urinary tract symptoms medication on the functional performance of holmium laser enucleation of the prostate.术前下尿路症状药物治疗对钬激光前列腺剜除术功能表现的影响。
Cent European J Urol. 2021;74(3):429-436. doi: 10.5173/ceju.2021.130. Epub 2021 Aug 13.
6
Questionnaire survey assessing seasonal changes in lower urinary tract symptoms in men with benign prostate hyperplasia.评估良性前列腺增生男性下尿路症状季节性变化的问卷调查
Turk J Urol. 2020 Nov;46(6):468-473. doi: 10.5152/tud.2020.20185. Epub 2020 Oct 9.
7
Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.整合多项患者报告结局评估良性前列腺增生相关下尿路症状的项目反应理论建模。
AAPS J. 2020 Jul 29;22(5):98. doi: 10.1208/s12248-020-00484-7.
8
The role of adrenal derived androgens in castration resistant prostate cancer.肾上腺来源的雄激素在去势抵抗性前列腺癌中的作用。
J Steroid Biochem Mol Biol. 2020 Mar;197:105506. doi: 10.1016/j.jsbmb.2019.105506. Epub 2019 Oct 28.
9
Effects of barbed suture during robot-assisted radical prostatectomy on postoperative tissue damage and longitudinal changes in lower urinary tract outcome.机器人辅助根治性前列腺切除术中使用带倒刺缝线对术后组织损伤及下尿路结局纵向变化的影响。
Surg Endosc. 2018 Jan;32(1):145-153. doi: 10.1007/s00464-017-5649-z. Epub 2017 Jun 22.
10
Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.联合治疗对良性前列腺增生患者相关结局指标的影响:度他雄胺和坦索罗辛的临床应用价值
Patient Relat Outcome Meas. 2011 Jul;2:71-9. doi: 10.2147/PROM.S13062. Epub 2011 Mar 31.